Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition

Chou, Chia-Hsuan; Lu, Ko-Hsiu; Yang, Jyh Bin; Hsieh, Yi‐Hsien; Lin, Chiao‐Wen

doi:10.1016/j.phymed.2021.153642

Cited by 22 publications

(22 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, microRNA‐101 was shown to promote NPC apoptosis through inhibiting MEK1 expression to alleviate ERK/MAPK signaling pathway and survivin expression 50 . Moreover, Chou and colleagues reported that DHM suppresses cell metastasis in human osteosarcoma through ERK pathway 51 . In our study, DHM likewise was shown to inhibit NPC metastasis via a suppression of phosphorylation of ERK1/2.…”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases‐2 expression in human nasopharyngeal carcinoma through extracellular signal‐regulated kinase signaling pathway

Huang

Wang

et al. 2022

Environmental Toxicology

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asia and the main cause of treatment failure is metastasis. A lot of biological and pharmacological actions of dihydromyricetin (DHM) have been reported such as regulating glucose and anticancer effects. The effects of DHM on the cancer invasion and migration of NPC, however, are still unclear. We therefore investigated the in vitro anti-metastatic properties of DHM on three human NPC cell lines (HONE-1, NPC-39, and NPC-BM), as well as the underlying signaling pathways. Our study revealed that DHM could suppress the migration and invasion in NPC cells. Gelatin zymography assay and western blotting assays demonstrated that DHM suppressed the enzyme activity and protein expression of matrix metalloproteinases-2 (MMP-2). Mitogen-activated protein kinases were also investigated to elucidate the signaling pathway, which showed that phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) was inhibited after the treatment of DHM. In conclusion, our data revealed that DHM inhibited the migration and invasion of NPC cells by suppressing the expression of MMP-2 via down regulating the ERK1/2 signaling pathway.

show abstract

Section: Discussionsupporting

confidence: 69%

“…50 Moreover, Chou and colleagues reported that DHM suppresses cell metastasis in human osteosarcoma through ERK pathway. 51 In our study, DHM likewise was shown to inhibit NPC metastasis via a suppression of phosphorylation of ERK1/2.…”

Section: Discussionsupporting

confidence: 56%

Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases‐2 expression in human nasopharyngeal carcinoma through extracellular signal‐regulated kinase signaling pathway

Huang

Wang

et al. 2022

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…It is known that the urokinase plasminogen activator (uPA) is a serine proteinase that increases the amount of plasmin generated by plasminogen, thereby disrupting the extracellular matrix (ECM) and promoting cancer invasion and migration [ 45 ]. DHM has been found to reduce the expression of transcriptional factorS SP-1 and NF-κB from the cytoplasm to the nucleus via the ERK pathway, thereby reducing the ability of SP-1 and NF-κB to bind to the downstream uPA promoter, resulting in downregulation of uPA expression, and ultimately suppressing osteosarcoma metastasis [ 46 ]. Matrix metalloproteinases (MMPs) are members of a family of zinc-dependent proteolytic enzymes.…”

Section: The Anticancer Potential and Underlying Mechanisms Of Dihydr...mentioning

confidence: 99%

Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer

Xiao

Zhu

et al. 2022

Cancers

View full text Add to dashboard Cite

Dihydromyricetin (DHM) is a natural flavonoid compound extracted from Ampelopsis grossedentata that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. In addition, DHM inhibits the progression of cancers such as lung cancer, hepatocellular cancer, breast cancer, melanoma, and malignant reproductive systems through multiple mechanisms, including antiangiogenesis, antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, DHM also activates autophagy at different levels, exerting a dual-regulatory effect on cancers. Mechanistically, DHM can effectively regulate mammalian target of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-κB (NF-κB), p53, and endoplasmic reticulum stress (ER stress)-driven signaling in different types of cancers. DHM has also been shown to have inhibitory effects on various regulators that trigger epithelial–mesenchymal transition (EMT). Furthermore, DHM exhibits a remarkable anticancer reversal ability when used in combination with drugs such as adriamycin, nedaplatin, and other drugs. However, the low bioavailability of DHM limits its potential applications, which are improved through structural modification and the exploration of novel dosage forms. Therefore, DHM may become a promising candidate for treating malignancies alone or combined with conventional anticancer strategies used in clinical practice.

show abstract

“…As is the case for oral mucositis, the number of tissue-infiltrating inflammatory cells is elevated in low-risk OPMDs as compared to healthy oral mucosa, being further augmented in high-risk OPMDs and OSCCs [ 105 ]. In these pathological settings, leucocytes release cytokines, among which interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)α are particularly abundant [ 79 , 108 , 109 ]. Specifically, in parallel with the increase in the number of infiltrating leukocytes, the levels of the abovementioned cytokines progressively augment as the oral mucosa becomes the site of a chronic inflammation, an OPMD, and, finally, an invasive OSCC [ 79 , 108 , 109 ].…”

Section: Reciprocal Interaction Between Cd147 and Opmd/oscc-associate...mentioning

confidence: 99%

“…In these pathological settings, leucocytes release cytokines, among which interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)α are particularly abundant [ 79 , 108 , 109 ]. Specifically, in parallel with the increase in the number of infiltrating leukocytes, the levels of the abovementioned cytokines progressively augment as the oral mucosa becomes the site of a chronic inflammation, an OPMD, and, finally, an invasive OSCC [ 79 , 108 , 109 ]. This phenomenon has been confirmed in animal models of oral carcinogenesis [ 110 , 111 ].…”

Section: Reciprocal Interaction Between Cd147 and Opmd/oscc-associate...mentioning

confidence: 99%

The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview

Barillari

Melaiu

Gargari

et al. 2022

IJMS

View full text Add to dashboard Cite

Cluster of differentiation (CD)147, also termed extracellular matrix metalloprotease inducer or basigin, is a glycoprotein ubiquitously expressed throughout the human body, the oral cavity included. CD147 actively participates in physiological tissue development or growth and has important roles in reactive processes such as inflammation, immunity, and tissue repair. It is worth noting that deregulated expression and/or activity of CD147 is observed in chronic inflammatory or degenerative diseases, as well as in neoplasms. Among the latter, oral squamous cell carcinoma (OSCC) is characterized by an upregulation of CD147 in both the neoplastic and normal cells constituting the tumor mass. Most interestingly, the expression and/or activity of CD147 gradually increase as healthy oral mucosa becomes inflamed; hyperplastic/dysplastic lesions are then set on, and, eventually, OSCC develops. Based on these findings, here we summarize published studies which evaluate whether CD147 could be employed as a marker to monitor OSCC development and progression. Moreover, we describe CD147-promoted cellular and molecular events which are relevant to oral carcinogenesis, with the aim to provide useful information for assessing whether CD147 may be the target of novel therapeutic approaches directed against OSCC.

show abstract

Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition

Cited by 22 publications

References 55 publications

Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases‐2 expression in human nasopharyngeal carcinoma through extracellular signal‐regulated kinase signaling pathway

Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases‐2 expression in human nasopharyngeal carcinoma through extracellular signal‐regulated kinase signaling pathway

Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer

The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview

Contact Info

Product

Resources

About